UY32095A - Suspensiones submicrón farmacéuticas estabilizadas y métodos para formarlas - Google Patents

Suspensiones submicrón farmacéuticas estabilizadas y métodos para formarlas

Info

Publication number
UY32095A
UY32095A UY0001032095A UY32095A UY32095A UY 32095 A UY32095 A UY 32095A UY 0001032095 A UY0001032095 A UY 0001032095A UY 32095 A UY32095 A UY 32095A UY 32095 A UY32095 A UY 32095A
Authority
UY
Uruguay
Prior art keywords
stapilized
methods
submicron suspension
pharmaceutical
pharmaceutical submicron
Prior art date
Application number
UY0001032095A
Other languages
English (en)
Inventor
Ernesto J Castillo
Masood A Chowhan
Asgharian Bahram
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41353867&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY32095(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of UY32095A publication Critical patent/UY32095A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

El presente invento se dirige a una suspensión submicrón farmacéutica y un método para formar la suspensión submicrón .- La suspensión submicrón es útil para el suministro de un agente terapéutico relativamente hidrofóbico y/o de baja solubilidad.- la suspensión submicrón y el método para la formación de la suspensión submicrón, típicamente emplean un material polimérico que ayuda en la prevención de la agregación del agente terapéutico.
UY0001032095A 2008-09-19 2009-09-07 Suspensiones submicrón farmacéuticas estabilizadas y métodos para formarlas UY32095A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9828008P 2008-09-19 2008-09-19

Publications (1)

Publication Number Publication Date
UY32095A true UY32095A (es) 2010-01-29

Family

ID=41353867

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032095A UY32095A (es) 2008-09-19 2009-09-07 Suspensiones submicrón farmacéuticas estabilizadas y métodos para formarlas

Country Status (27)

Country Link
US (3) US20100076045A1 (es)
EP (2) EP2425815B1 (es)
JP (3) JP5739809B2 (es)
KR (1) KR101682924B1 (es)
CN (2) CN104688682A (es)
AR (2) AR073597A1 (es)
AU (1) AU2009293400B2 (es)
BR (1) BRPI0919199B8 (es)
CA (1) CA2736106C (es)
CL (1) CL2009001856A1 (es)
CY (1) CY1119740T1 (es)
DK (1) DK2425815T3 (es)
ES (2) ES2592503T3 (es)
HK (1) HK1152258A1 (es)
HR (1) HRP20180050T1 (es)
HU (1) HUE037933T2 (es)
LT (1) LT2425815T (es)
MX (1) MX348204B (es)
NO (1) NO2425815T3 (es)
PL (2) PL2328551T3 (es)
PT (2) PT2425815T (es)
RU (1) RU2521258C2 (es)
SI (1) SI2425815T1 (es)
TW (1) TWI580441B (es)
UY (1) UY32095A (es)
WO (1) WO2010033528A1 (es)
ZA (1) ZA201101398B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
CN102438979A (zh) * 2009-03-12 2012-05-02 麦迪凯姆股份公司 苯甲酰基苯乙酰胺衍生物的新型晶体
EP3520749A1 (en) 2010-10-15 2019-08-07 Clearside Biomedical, Inc. Device for ocular access
BR112013014044A2 (pt) * 2010-12-06 2017-10-31 Degama Barrier Ltd composição, produto alimentício e processo para prepará-lo
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
WO2013166408A1 (en) 2012-05-03 2013-11-07 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
NZ728721A (en) * 2012-05-03 2018-05-25 Kala Pharmaceuticals Inc Pharmaceutical nanoparticles showing improved mucosal transport
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
EP2844295A1 (en) 2012-05-03 2015-03-11 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US10500282B2 (en) * 2012-12-19 2019-12-10 Kashiv Biosciences, Llc Supersaturated stabilized nanoparticles for poorly soluble drugs
AU2014216178B2 (en) 2013-02-15 2018-06-28 KALA BIO, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
BR112015020139A2 (pt) 2013-02-20 2017-07-18 Kala Pharmaceuticals Inc compostos terapêuticos e usos dos mesmos
JP6379183B2 (ja) 2013-05-03 2018-08-22 クリアサイド バイオメディカル，インコーポレイテッド 眼球注射の装置および方法
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
KR20160099084A (ko) 2013-11-01 2016-08-19 칼라 파마슈티컬스, 인크. 치료 화합물의 결정질 형태 및 그의 용도
WO2016036588A1 (en) * 2014-09-03 2016-03-10 Merck Sharp & Dohme Corp. Pharmaceutical suspensions containing etoricoxib
JP2019514581A (ja) 2016-05-02 2019-06-06 クリアサイド バイオメディカル，インコーポレイテッド 眼の薬物送達のためのシステムおよび方法
CN110177527B (zh) 2016-08-12 2022-02-01 科尼尔赛德生物医学公司 用于调节药剂递送用针的插入深度的装置和方法
AU2017324716B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
CN109688818A (zh) 2016-09-08 2019-04-26 卡拉制药公司 治疗化合物的晶型及其用途
EP3509422A4 (en) 2016-09-08 2020-05-20 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
US20190216824A1 (en) * 2016-09-16 2019-07-18 Kala Pharmaceuticals, Inc. Particles, Compositions and Methods for Ophthalmic and/or Other Applications
CN114206348A (zh) * 2019-04-16 2022-03-18 科尼尔赛德生物医学公司 可注射曲安奈德配制品

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5466680A (en) * 1992-03-26 1995-11-14 Cytologics, Inc. Method and compositions for enhancing white blood cell functioning on a mucosal or cutaneous surface
ES2079994B1 (es) * 1992-10-07 1996-08-01 Cusi Lab Formulacion farmaceutica a base de polimixina-trimetoprim y un agente antiinflamatorio para su utilizacion topica oftalmica y otica.
US5298262A (en) * 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5429824A (en) * 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
WO1995005803A1 (en) 1993-08-20 1995-03-02 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
US5718919A (en) * 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
US6375986B1 (en) * 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US6969529B2 (en) * 2000-09-21 2005-11-29 Elan Pharma International Ltd. Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
ES2303527T3 (es) * 2000-05-10 2008-08-16 Jagotec Ag Procedimiento de molienda.
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
RU2219910C2 (ru) * 2002-01-08 2003-12-27 Институт органической и физической химии им. А.Е.Арбузова КНЦ РАН Ветеринарный имплантируемый препарат иммуностимулирующего действия (варианты)
US7138468B2 (en) * 2002-03-27 2006-11-21 University Of Southern Mississippi Preparation of transition metal nanoparticles and surfaces modified with (CO)polymers synthesized by RAFT
WO2004006959A1 (en) * 2002-07-16 2004-01-22 Elan Pharma International, Ltd Liquid dosage compositions of stable nanoparticulate active agents
CA2513006A1 (en) * 2003-01-15 2004-08-05 Dow Global Technologies Inc. Drug particles obtained by freezing onto a cold surface
US20040235892A1 (en) * 2003-05-22 2004-11-25 Yujia Dai Indazole and benzisoxazole kinase inhibitors
CA2539023A1 (en) 2003-09-23 2005-04-14 Alcon Inc. Triamcinolone acetonide and anecortave acetate formulations for injection
US20060141049A1 (en) * 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
WO2005072710A2 (en) * 2004-01-28 2005-08-11 Johns Hopkins University Drugs and gene carrier particles that rapidly move through mucous barriers
WO2006043172A1 (en) * 2004-10-19 2006-04-27 Pfizer Inc. Pharmaceutical compositions and methods for sub-tenon delivery
WO2006062875A1 (en) * 2004-12-08 2006-06-15 Merck & Co., Inc. Ophthalmic nanoparticulate formulation of a cyclooxygenase-2 selective inhibitor
TW200640443A (en) 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
KR20080002939A (ko) * 2005-04-12 2008-01-04 엘란 파마 인터내셔널 리미티드 나노입자형 퀴나졸린 유도체 제제
EP1874267A1 (en) * 2005-04-13 2008-01-09 Pfizer Products Inc. Injectable depot formulations and methods for providing sustained release of poorly soluble drugs comprising nanoparticles
US7893040B2 (en) * 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
JP5112669B2 (ja) * 2005-09-30 2013-01-09 富山化学工業株式会社 難溶性薬物のナノ微粒子を含有する水性懸濁液剤
US20070149480A1 (en) * 2005-12-23 2007-06-28 Alcon, Inc. PHARMACEUTICAL COMPOSITION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
US20070196350A1 (en) * 2006-02-22 2007-08-23 Bartels Stephen P Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment

Also Published As

Publication number Publication date
HUE037933T2 (hu) 2018-09-28
WO2010033528A1 (en) 2010-03-25
CL2009001856A1 (es) 2010-12-31
CN104688682A (zh) 2015-06-10
HRP20180050T1 (hr) 2018-02-09
PL2425815T3 (pl) 2018-03-30
JP5739809B2 (ja) 2015-06-24
PL2328551T3 (pl) 2017-04-28
AR124648A2 (es) 2023-04-19
CN102176898A (zh) 2011-09-07
EP2425815B1 (en) 2017-10-25
ES2657455T3 (es) 2018-03-05
ZA201101398B (en) 2012-04-25
JP2015052020A (ja) 2015-03-19
LT2425815T (lt) 2018-01-25
KR101682924B1 (ko) 2016-12-06
EP2328551A1 (en) 2011-06-08
ES2592503T3 (es) 2016-11-30
CA2736106C (en) 2016-08-16
KR20110054055A (ko) 2011-05-24
JP2012503003A (ja) 2012-02-02
JP2017043637A (ja) 2017-03-02
BRPI0919199B1 (pt) 2020-10-27
DK2425815T3 (da) 2018-01-29
RU2521258C2 (ru) 2014-06-27
NO2425815T3 (es) 2018-03-24
HK1152258A1 (zh) 2012-02-24
US20170216228A1 (en) 2017-08-03
TWI580441B (zh) 2017-05-01
TW201014612A (en) 2010-04-16
AU2009293400B2 (en) 2015-05-07
EP2328551B1 (en) 2016-06-15
MX2011002494A (es) 2011-04-07
US20100076045A1 (en) 2010-03-25
SI2425815T1 (en) 2018-02-28
EP2425815A1 (en) 2012-03-07
AU2009293400A1 (en) 2010-03-25
AR073597A1 (es) 2010-11-17
CA2736106A1 (en) 2010-03-25
PT2328551T (pt) 2016-09-22
MX348204B (es) 2017-05-30
US20140294970A1 (en) 2014-10-02
CY1119740T1 (el) 2018-09-05
BRPI0919199B8 (pt) 2021-05-25
PT2425815T (pt) 2018-01-31
BRPI0919199A2 (pt) 2015-12-15
RU2011115211A (ru) 2012-10-27

Similar Documents

Publication Publication Date Title
UY32095A (es) Suspensiones submicrón farmacéuticas estabilizadas y métodos para formarlas
DOP2016000244A (es) Nanopartículas terapéuticas que comprenden un agente terapéutico, y formas para su elaboración y uso
NI201600037A (es) Nanopartículas poliméricas terapéuticas y métodos para su elaboración y uso.
UY35070A (es) ?Sistemas de administración y formulación de fármacos de retención gástrica, y método para su preparación usando carbonato de calcio funcionalizado?.
AR091959A1 (es) Agentes de sosten sinteticos y agentes de sosten monodispersos y metodos para la elaboracion de los mismos
UY36313A (es) Composición que comprende un carbonato de calcio reaccionado en la superficie como agente antiaglomerante, y método para producirla
BR112013028400A2 (pt) nanocompósitos de tereftalato de polietileno-grafeno
AR092957A1 (es) Formulacion de forma farmaceutica solida de desintegracion veloz que comprende carbonato de calcio funcionalizado y metodo para su fabricacion
UY35025A (es) Composición de lechada de cal de gran finura
GT200600259A (es) Proceso de elaboracion para tigeciclina
DOP2015000006A (es) Formulaciones de etanercept que muestran una marcada reducción de la cantidad de partículas subvisibles
PH12017502155A1 (en) Formation of cyclosporin a/cyclodextrin nanoparticles
CR20160438A (es) Dispersión sólida amorfa que comprende taxano, comprimido que comprende la misma, y método para su preparación
AR091121A1 (es) Producto de construccion que comprende particulas de sulfato de calcio dihidrato aglutinadas por un aglutinante organico y metodo para manufacturarlo
RS54733B1 (sr) Tritokvalin za upotrebu u tretiranju cistične fibroze
CL2015002817A1 (es) Formulación del l-5-metiltetrahidrofolato de calcio amorfo (l-5-mthf-ca).
CL2015001330A1 (es) Collar ampliador para contenedores
BR112017000022A2 (pt) nanoparticulas terapêuticas direcionadas a alvo e métodos de produção e uso dessas partículas
CY1120700T1 (el) Ενωσεις τριαμινοπυριμιδινης χρησιμες για προληψη ή αγωγη ελονοσιας
CO7131356A2 (es) Método para producir clorhidrato de anamorelina que tiene contenido controlado de cloruro
MX2018011760A (es) Aducto de ciclodextrina-panobinostat.
AR075686A1 (es) Nanoparticulas de policosanol
ES2723284T3 (es) Un procedimiento para la preparación de partículas de carga floculadas
GB201208080D0 (en) Tobramycin formulation
IN2014CH02034A (es)

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20181114